Dr. V. Mohan Diabetes Specialist’s Post

New #Articles in #Diabetes and #Metabolic Syndrome: #Clinical #Research/#Reviews (Ranked 6/244 among Diabetes/Endo journals globally) #Global #research trends and hotspots in #gestationaldiabetes and long-term #cardiovascular #health: A #bibliometricanalysis https://lnkd.in/dYaYE2W

🤗Editor's Choice: Pathogenesis of Distal Symmetrical Polyneuropathy in Diabetes 🎓by Prof. Alun Huw Davies et al., from the Imperial College London. 🧐Enjoy reading: https://lnkd.in/es2m9wZV #diabetes; #diabetic neuropathy; #distal symmetrical polyneuropathy; #neuropathic pain; pathogenesis; #hyperglycemia; #central nervous system; #glycemic control; #pain management; #spinal cord stimulation

This observation was too significant to not highlight on its own. The research on semaglutide was started prior to the pandemic and therefore the data is less likely to be skewed to support a narrative. It clearly shows an almost double increase in cardiovascular events after 2022 but beginning in late 2021. There is an "elephant in the room", unless there is a better explanation for the almost 100% increase in cardiovascular events. Would it be unreasonable for the researchers to do further analysis on the data to clarify? It would be valuable to understand as it could delineate population risks. Link to paper in comments. #covid #medicine #research

"This really has the potential to revolutionize blood pressure care worldwide," says Adam Gepner, MD, clinical associate adjunct professor, Cardiovascular Medicine. Read more: https://lnkd.in/gTkeh5xG

Let’s first look at what he authors said before pointing to what Dr Philip McMillan has wrong… “Deaths during the COVID-19 pandemic were at times more challenging to adjudicate because of limited medical information; however, unknown deaths were conservatively categorized as CV death and should not have led to any treatment bias. “ Therefore it is clear that CV were overestimated, and that too many of deaths authors related as CV such were not CV related. Factors that increased CV risk during the pandemic were obesity, lack of exercice and lack of screening/ CV care. ”Epidemiologic studies report a U-shaped relationship between non-CV death and BMI and even suggest an “obesity paradox” whereby increased BMI is associated with better outcomes. In a randomized clinical trial, many of the confounding comorbidities associated with poorer outcomes and lower BMI are excluded. There was an associated increased risk of respiratory decompensation and mortality in patients with COVID-19 and obesity and plausible biologic hypotheses associating obesity with adverse COVID outcomes, including impaired respiratory status, lower cardiometabolic reserve, or immune hyperreactivity or dysregulation.” As seen CV deaths are linked to COVID. Increases in CV deaths were seen between 2019 and 2021 but drops afterwards according to the literature (attached reference). “All-cause ASMRs for CVD increased notably during the initial two years of the COVID-19 pandemic and then witnessed a decline in 2021–2023. The cohorts (the young, males and minorities) with the steepest rise in mortality decreased at the fastest rate instead.” And to finish all, the authors stated that “all comparisons following CV death should be treated as hypothesis generating because CV death did not meet the prespecified P value.” Non significance means no relevancy… Maybe Dr Philip McMillan should have read the full paper prior to making conclusions. The elephant in the room might simply be lack of such reading, and putting things in perspective… While wanting to link such deaths to vaccines, it is proven wrong…Again. https://lnkd.in/eUzF_rev

#HighlyCitedPapers   📝 The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs — Silbernagel, et al.   In this paper, the authors observed association with cardiovascular mortality and a biomarker of small dense LDL by studying the the LDL-Apolipoprotein B to LDL-Cholesterol Ratio in patients with cardiovascular complications.   Full text is available 👇 https://lnkd.in/dZu7HEU9   #medicine #health #research #science

📊 Breaking Research: Understanding GLP-1 Medications A groundbreaking study published in Nature Medicine reveals the broader impact of GLP-1 medications (like Ozempic) beyond their primary use for diabetes management. Analyzing health records of over 2.6 million patients, researchers uncovered 42 potential benefits and 19 possible risks. Key Benefits Discovered 🔍: · Reduced risk of blood clots, strokes, and heart attacks · Lower incidence of psychotic disorders and seizures · Decreased risk of bacterial infections and pneumonia · Potential protective effects against Parkinson's and Alzheimer's Important Considerations ⚠️ While generally safe, researchers identified rare but notable risks, including: · Kidney stones (possibly linked to reduced fluid intake) · Pancreatitis · Blood pressure fluctuations · Joint-related issues 💭 "The biology is complex... GLP-1 receptor in the body has an intricate web of various effects," notes lead researcher Dr. Ziyad Al-Aly from Washington University in St. Louis. What's your experience with GLP-1 medications? Have you noticed any unexpected effects - positive or negative - that weren't initially discussed with your healthcare provider? Share your journey below! Reference: https://lnkd.in/gzFjmgUY #HealthResearch #MedicalInnovation #Healthcare #ObesityTreatment #DiabetesCare #ClinicalResearch

In this post hoc analysis, the authors evaluated the effect of tirzepatide on glycemic levels, cardiometabolic markers, and body weight, and compared the clinical characteristics of individuals with early- and later-onset T2DM. The study’s findings are published in the journal Diabetes Care. Read more on MD Newsline https://lnkd.in/gWFtnapQ

Medical experts are adding broader measurements like heart health to the obesity diagnosis benchmark! The intention is to shift from BMI alone to include body fat, organ health, and functional assessments. This well-rounded personalized diagnosis acknowledges the “nuanced reality of obesity” says Robert Eckel, emeritus professor of medicine at the University of Colorado Anschutz Medical Campus and one of the group’s members. The new definition, put fourth by Lancet Laboratories Diabetes and Endocrinology Commission was endorsed by 76 organizations including World Obesity Federation, the American Heart Association and Britain’s Royal College of Physicians. Learn more about the implications for the healthcare industry and patients in Ashleigh Furlong’s article for Bloomberg: https://lnkd.in/gPH38_qG

Another FIRST brought to you by Truveta. This #GLP-1 #research explored GLP-1 #discontinuation + reinitiation #drugtrends and factors for #obesity and #weightloss. Over 96K patients were analyzed, suggesting that weight change, income, gastrointestinal #adverseevents, and #comorbidities play significant roles. Learn more about the findings and see which groups are more likely to re-start medication below! #rwe #rwd #treatmenteffectiveness